Abbott outlines pharma growth strategies
This article was originally published in Scrip
Executive Summary
Richard Gonzalez, the proposed chairman and CEO of the new pharmaceutical company spinning out of Abbott Laboratories, told investors and analysts on a conference call 21 October that he expects to grow through a mixture of building out its current Humira (adalimumab) blockbuster and the $1 billion plus potential of several candidate therapies it has in its pipeline.